Abstract
Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis (P10-6.013)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have